Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
O75879
UPID:
GATB_HUMAN
Alternative names:
Cytochrome c oxidase assembly factor PET112 homolog
Alternative UPACC:
O75879; Q4W5M8; Q53GP4; Q9P0S6; Q9Y2B8
Background:
The Glutamyl-tRNA(Gln) amidotransferase subunit B, mitochondrial, also known as Cytochrome c oxidase assembly factor PET112 homolog, plays a crucial role in mitochondrial protein synthesis. It ensures the formation of correctly charged Gln-tRNA(Gln) by transamidating misacylated Glu-tRNA(Gln), a process vital for mitochondrial function and energy production.
Therapeutic significance:
Given its involvement in Combined oxidative phosphorylation deficiency 41, a mitochondrial disorder with severe outcomes, understanding the role of Glutamyl-tRNA(Gln) amidotransferase subunit B could open doors to potential therapeutic strategies. Targeting this protein's function might offer new avenues for treating or managing this lethal condition.